Astrana Health, Inc. (ASTH) — Fair Value Analysis

Base-case fair value (P50): $58.55 · Current price: $38.64 · Verdict: Undervalued

The Verdict on ASTH

Based on extensive Monte Carlo simulations, ASTRANA HEALTH INC (ASTH) appears Deeply Undervalued. Our analysis points to a median fair value (P50) of $58.55, significantly above its current trading price of $38.64. This represents a substantial +51.5% potential, suggesting a considerable disconnect between the market’s perception and the statistically probable intrinsic value of ASTH. The Monte Carlo framework accounts for a wide range of future scenarios, indicating robust upside.

How ASTH stacks up against peers

While ASTH's operational and financial health, categorized as "average," provides a foundational stability, its current market valuation at $38.64 presents a compelling entry point relative to its estimated fair value of $58.55. The "average" quality tier suggests that ASTH maintains a respectable position within its sector, yet the pronounced +51.5% gap implies that this quality is currently being overlooked by the market. This scenario is particularly interesting for investors seeking value in companies with solid fundamentals but understated valuations.

What this means for investors

The Monte Carlo simulations strongly support the "Deeply Undervalued" verdict for ASTH. The projected +51.5% from the current $38.64 to the median fair value of $58.55 signals a significant opportunity. For investors, this considerable margin of safety and potential for appreciation, despite an average quality tier, makes ASTH a noteworthy candidate for further due diligence. To understand the full spectrum of outcomes, including specific bear and bull case price targets and the probability distribution, sign up for a free FairCurve account and track ASTH's fair value as new fundamental data becomes available.